Challenges related to safety concerns in drug development persist as a significant hurdle for the pharmaceutical sector. Safety Pharmacology, as outlined by ICH S7A (2001), places a critical emphasis on the evaluation of drugs for off-target effects. In vitro Pharmacological profiling is now more frequently employed at the initial stages of drug discovery to detect unfavorable off-target activity profiles. These profiles, if identified post-approval, have the potential to impede candidate drug development or, in some cases, prompt market withdrawal. In vitro Pharmacological profiling now plays a vital role in scrutinizing how drug candidates interact with molecular targets distinct from their intended therapeutic targets. 

At ICE Bioscience, we've pioneered state-of-the-art functional safety panels. SafetyOne44™ is designed for 44 specific targets, while SafetyMax90™ stands as the most comprehensive functional safety panel available, encompassing up to 90 targets. We also provide specialized functional panels tailored to specific research areas, including CNS panels. Compared to binding assays, our functional assays offer the advantage of expertise in distinguishing between different modes of action.

These panels are used to study and assess how drugs interact with various molecular targets, including off-target interactions. This information is crucial for predicting and mitigating ADRs and ensuring the safety and efficacy of drug candidates during the drug development process.

Customize Your In Vitro Functional Safety Panels

ICE Bioscience leads in Safety Pharmacology services. Tailor your own panels to meet your specific drug discovery needs. Our experts and a vast portfolio of in vitro assays are at your service. Let us drive your drug discovery program forward.

Contact Us